Mahon, Fx., Rea, D., Guilhot, J., Guillot, F., Huguet, F., Nicolini, F., et al. (2010) Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Remission for at Least 2 Years: The Prospective, Multicenter Stop Imatinib (STIM) Trial. Lancet Oncology, 11, 1029-1035.
https://doi.org/10.1016/S1470-2045(10)70233-3

has been cited by the following article:

• TITLE: About a Case of Chronic Myeloid Leukemia and Pregnancy

  AUTHORS: M. A. D. Sengeyi, S. J. Mokassa, A. J. Lumaya, M. R. Mbungu, J. J. Malemba

  KEYWORDS: Chronic Myeloid Leukemia, Pregnancy, Tyrosine Kinase Inhibitors

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.11 No.9, September 16, 2021

  ABSTRACT: Chronic myeloid leukemia (CML) associated with pregnancy is a very rare situation (less than one case per 100,000 pregnancies). It raises a serious ethical and therapeutic problem because chemotherapy during pregnancy can expose the fetus to various complications such as congenital malformations, abortion and intra uterine growth restriction. Inhibitors of tyrosine kinase are the most widely used molecules but without much certainly about their non-teratogenic effects. This is a report case of pregnancy occurring in a patient with Imatinib for CML replaced by Hydrea who gave birth to a healthy newborn with no congenital malformation.